SOFIA BRUNI; MARÍA F. MERCOGLIANO; ROXANA SCHILLACI

INB03: a new immune checkpoint inhibitor that reprograms polarization and promotes ADCP in human macrophages

SITC Annual meeting

Año: 2023;

MAURO, FLORENCIA L.; SOFIA BRUNI; DUPONT, AGUSTINA; INURRIGARRO, GLORIA; FIGURELLI, SILVINA; BARCHUK, SABRINA; LOPEZ DELLA VECCHIA, DANIEL; CORDO-RUSSO, ROSALIA I.; DEZA, ERNESTO GIL; MARÍA F. MERCOGLIANO; ROXANA SCHILLACI

New therapeutic approach for triple negative breast cancer: soluble TNFα blockade and MUC4 expression as a prognostic biomarker

AACR Annual Meeting

Año: 2023;

SOFIA BRUNI; MAURO, FLORENCIA L.; SOFIA NAVEIRO; MARÍA F. MERCOGLIANO; ROXANA SCHILLACI

Soluble TNFα blockade improves effectiveness of trastuzumab deruxtecan and boosts antitumor potential of macrophages in a HER2+ tumor model

AACR Annual Meeting

Año: 2023;

SOFIA BRUNI; MAURO, FLORENCIA L.; ROLDAN DEAMICIS, AGUSTINA; MARA DE MARTINO; MARÍA F. MERCOGLIANO; PATRICIA V. ELIZALDE; ROXANA SCHILLACI

MUC4 enables immune tumor evasion in HER2+ breast cancer

AACR ANNUAL MEETING

Año: 2022;

SOFIA BRUNI; MARA DE MARTINO; MAURO, FLORENCIA L.; MARÍA F. MERCOGLIANO

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression

SITC ANNUAL MEETING

Año: 2022;

SOFIA BRUNI; MAURO, FLORENCIA L.; CECILIA J. PROIETTI; CORDO-RUSSO, ROSALIA I.; MARÍA F. MERCOGLIANO; ROXANA SCHILLACI

Soluble TNFα blockade enhances trastuzumab deruxtecan antitumor effect in HER2-positive breast cancer model

San Antonio Breast Cancer Symposium

Año: 2022;

SOFIA BRUNI; MARA DE MARTINO; MAURO, FLORENCIA L.; MARÍA F. MERCOGLIANO; ROXANA SCHILLACI

Soluble TNFα blockade sensitizes HER2-positive breast cancer to trastuzumab and promotes macrophage-NK cell collaboration to subvert immunosuppression

SOCIEDAD ARGENTINA DE INVESTIGACION CLINICA

Año: 2022;

SOFIA BRUNI; MAURO, FLORENCIA L.; ROLDAN DEAMICIS, AGUSTINA; MARA DE MARTINO; MARÍA F. MERCOGLIANO; PATRICIA V. ELIZALDE; ROXANA SCHILLACI

Soluble tumor necrosis factor alpha fosters tumor growth, innate immune evasion and resistance to lapatinib in HER2-positive breast cancer

BUENOS AIRES BREAST CANCER SYMPOSIUM

Año: 2021;

SOFIA BRUNI; MAURO, FLORENCIA L.; ROLDAN DEAMICIS, AGUSTINA; MARA DE MARTINO; MARÍA F. MERCOGLIANO; PATRICIA V. ELIZALDE; ROXANA SCHILLACI

MUC4 enables immune tumor evasion in HER2+ breast cancer

SOCIEDAD ARGENTINA DE INVESTIGACION CLINICA

Año: 2021;

ROXANA SCHILLACI; SOFIA BRUNI; MAURO, FLORENCIA L.; MARÍA FLORENCIA MERCOGLIANO; ROLDAN DEAMICIS, AGUSTINA; CECILIA J. PROIETTI; CORDO-RUSSO, ROSALIA I.; INURRIGARRO, GLORIA; DUPONT, AGUSTINA; CARLA ADAMI; LOPEZ DELLA VECCHIA, DANIEL; BARCHUK, SABRINA; FIGURELLI, SILVINA; DEZA, ERNESTO GIL; SANDRA ARES; FELIPE GERCOVICH; PATRICIA V. ELIZALDE

Mucin 4 expression in high risk breast cancer: Predicting and overcoming resistance to immunotherapy

SAN ANTONIO BREAST CANCER SYMPOSIUM

Año: 2021;

SOFIA BRUNI; MAURO, FLORENCIA L.; ROLDAN DEAMICIS, AGUSTINA; DE MARTINO, MARA; MARÍA F. MERCOGLIANO; PATRICIA V. ELIZALDE; ROXANA SCHILLACI

Soluble TNFα blockade overcomes lapatinib resistance and unleashes an innate immune response in HER2+ breast cancer

SOCIEDAD ARGENTINA DE INVESTIGACION CLINICA

Año: 2020;

BRUNI, SOFÍA; MAURO, FLORENCIA L.; ROLDAN DEAMICIS, AGUSTINA; DE MARTINO, MARA; MERCOGLIANO, MARÍA F.; ELIZALDE, PATRICIA V.; SCHILLACI, ROXANA

Soluble TNFα blockade inhibits cell migration, tumor growth, and induces innate immune response in lapatinib-resistant HER2+ breast cancer

Frontiers in Cancer Immunotherapy 2020

Año: 2020;

BRUNI, SOFÍA; MAURO, FLORENCIA L.; ROLDAN DEAMICIS, AGUSTINA; DE MARTINO, MARA; MERCOGLIANO, MARÍA F.; ELIZALDE, PATRICIA V.; SCHILLACI, ROXANA

Soluble TNFα overcomes lapatinib resistance in HER2+ breast cancer

AACR Virtual Annual Meeting

Año: 2020;

BRUNI, SOFÍA; DE MARTINO, MARA; MAURO, FLORENCIA L.; SANTA MARIA DE LA PARRA, LUCIA; ELIZALDE, PATRICIA V.; SCHILLACI, ROXANA

Soluble TNFα induced mucin 4 is a mediator of trastuzumab resistance and of an immunosuppressive tumor microenvironment in HER2+ breast cancer

Society of Immunotherapy and Cancer Annual Meeting

Año: 2019;

BRUNI, SOFÍA; DE MARTINO, MARA; MAURO, FLORENCIA L.; MERCOGLIANO, MARÍA F.; ELIZALDE, PATRICIA V.; SCHILLACI, ROXANA

MUC4 is the principal mediator of TNFα-induced trastuzumab resistance and fosters an immunosuppressive tumor microenvironment in HER2+ breast cancer

Sociedad Argentina de Investigación Clínica

Año: 2019;

BRUNI, SOFÍA; DE MARTINO, MARA; PROIETTI, CECILIA J.; ELIZALDE, PATRICIA V.; SCHILLACI, ROXANA

TNFα blockade improves antitumor innate immune response and overcomes trastuzumab resistance in HER2+ breast cancer

Sociedad Argentina de Investigación Clínica

Año: 2018;

BRUNI, SOFÍA; DE MARTINO, MARA; PROIETTI, CECILIA J.; ELIZALDE, PATRICIA V.; SCHILLACI, ROXANA; MERCOGLIANO, MF.

TNFα blockade overcomes trastuzumab and pertuzumab resistance in HER2 positive breast cancer?

Reunión Conjunta de Sociedades de Biociencias

Año: 2017;

MARÍA F. MERCOGLIANO; MARA DE MARTINO ; SOFIA BRUNI; LEANDRO VENTURUTTI; MARTÍN RIVAS ; MATÍAS AMASINO ; CECILIA J. PROIETTI ; PATRICIA V. ELIZALDE; ROXANA SCHILLACI

TNF alpha induces multiresistance to HER2 targeted therapies in HER2 positive breast cancer

American Association for Cancer Research, Annual Meeting

Lugar: Washington, DC; Año: 2017;

SOFIA BRUNI ; MARA DE MARTINO; CECILIA PROIETTI ; PATRICIA V. ELIZALDE; ROXANA SCHILLACI ; MARÍA FLORENCIA MERCOGLIANO

TNF induces multiresistance to HER2-targeted therapies in breast cancer

Sociedad Argentina de Investigación Clínica, Congreso Anual

Lugar: Mar del Plata; Año: 2016;